Clinical Manifestations, Current and Future Therapy, and Long-Term Outcomes in Congenital Thrombotic Thrombocytopenic Purpura

• Published in: Journal of clinical medicine Vol. 12; no. 10; p. 3365
• Main Authors: Sakai, Kazuya, Matsumoto, Masanori
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 09.05.2023; MDPI
• Subjects: ADAMTS13; Anemia; Apheresis; Bacterial infections; Care and treatment; Clinical medicine; Cohort analysis; Congenital diseases; congenital thrombotic thrombocytopenic purpura; Diagnosis; fresh frozen plasma; Genetic disorders; Mutation; Patient outcomes; Patients; Plasma; prophylaxis; Purpura; quality of life; Review; Thrombocytopenia; Thrombocytopenic purpura; Japan; fresh frozen plasma; ADAMTS13; congenital thrombotic thrombocytopenic purpura; quality of life; prophylaxis
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12103365

Congenital thrombotic thrombocytopenic purpura (cTTP) is an extremely rare disease characterized by the severe deficiency of a disintegrin and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS13), caused by mutations. While ADAMTS13 supplementation by fresh frozen plasma (FFP) infusion immediately corrects platelet consumption and resolves thrombotic symptoms in acute episodes, FFP treatment can lead to intolerant allergic reactions and frequent hospital visits. Up to 70% of patients depend on regular FFP infusions to normalize their platelet counts and avoid systemic symptoms, including headache, fatigue, and weakness. The remaining patients do not receive regular FFP infusions, mainly because their platelet counts are maintained within the normal range or because they are symptom-free without FFP infusions. However, the target peak and trough levels of ADAMTS13 to prevent long-term comorbidity with prophylactic FFP and the necessity of treating FFP-independent patients in terms of long-term clinical outcomes are yet to be determined. Our recent study suggests that the current volumes of FFP infusions are insufficient to prevent frequent thrombotic events and long-term ischemic organ damage. This review focuses on the current management of cTTP and its associated issues, followed by the importance of upcoming recombinant ADAMTS13 therapy.